Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Anti-CD22:TCRz:4-1BB T-cells in Patient With CD22-Positive Recurrent Lymphoma That is Resistant or Refractory to Prior Anti-CD22:TCRz:CD28 Immunotherapy

NCT02721407 is registered in ClinicalTrials.gov with Xinqiao Hospital of Chongqing as lead sponsor.

NCT NCT02721407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02721407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Anti-CD22:TCRz:4-1BB T-cells in Patient With CD22-Positive Recurrent Lymphoma That is Resistant or Refractory to Prior Anti-CD22:TCRz:CD28 Immunotherapy
Lead sponsor
Xinqiao Hospital of Chongqing
Phase
Phase 1
Overall status
Unknown status
Start date
March 31, 2016
Completion date
December 31, 2019
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent adult diffuse large cell lymphoma, recurrent follicular lymphoma, recurrent mantle cell lymphoma, stage iii/iv adult diffuse large cell lymphoma, stage iii/iv follicular lymphoma, stage iii/iv mantle cell lymphoma